All products / Type / Easy Pen
Tirzepatide 10mg Easy Pen
Dual GIP/GLP-1 receptor agonist — weight, glucose, heart & liver research
SKU: EP-TIR-10-1
99% Purity$220
- Format
- Easy Pen
- Dosage
- 0.05mg per click
- Capacity
- 10 mg
Potential benefits
- Weight-loss research
- Glycemic-control research
- Cardiometabolic research
- Cardiometabolic & renal research endpoints
- Lipid-profile research
- Lean-mass preservation
- Appetite & satiety research
- Visceral & liver-fat research
Tirzepatide is a dual agonist studied for its activation of both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors, combining two metabolic pathways in one injectable. This “twincretin” approach is under research for endpoints including weight reduction, insulin sensitivity, fat and liver metabolism, and cardiovascular and kidney outcomes across multiple studies. In trials, tirzepatide has been studied against GLP-1-only therapies, with reported endpoints including up to roughly 20% body-weight reduction, HbA1c reductions, and cardiometabolic measures.
It is studied as a multi-system metabolic agent in research focused on metabolic endpoints. Research on Tirzepatide as a dual GIP/GLP-1 receptor agonist shows promising results:
GIP receptor activation enhances meal-induced insulin secretion and promotes fat metabolism.
GLP-1 receptor activation improves glucose control, induces satiety, and delays gastric emptying.
Combined, these mechanisms are studied for effects on appetite, blood-glucose regulation, fat metabolism, and metabolic organs such as the heart and liver.
It is studied as a multi-system metabolic agent in research focused on metabolic endpoints. Research on Tirzepatide as a dual GIP/GLP-1 receptor agonist shows promising results:
GIP receptor activation enhances meal-induced insulin secretion and promotes fat metabolism.
GLP-1 receptor activation improves glucose control, induces satiety, and delays gastric emptying.
Combined, these mechanisms are studied for effects on appetite, blood-glucose regulation, fat metabolism, and metabolic organs such as the heart and liver.
- In SURMOUNT‑1, up to 20.9% body weight reduction at 72 weeks (15 mg dose); most users lose ≥20%.
- Dose-dependent HbA1c reductions reported in diabetes trials versus GLP-1-only agents.
- Reductions in abdominal adiposity and liver fat with associated changes in NAFLD/MASLD biomarkers reported in research.
- In the SUMMIT HFpEF trial, a 38% lower risk of cardiovascular death or worsening heart failure was reported, alongside changes in cardiometabolic and lipid markers.
- Observational studies show reduced risk of major cardiovascular events, kidney outcomes, and death.
- Reductions in total cholesterol, LDL, and triglycerides with increased HDL reported in research.
- Fat-mass loss with preservation of lean mass studied in research.
- Dual-hormone action studied for effects on satiety, appetite, and energy intake.
References
| Molecular formula | C227H352N48O70 |
|---|---|
| Molecular weight | 4813.5 Da |
| CAS number | 2023788-19-2 |
| Purity | 99% |
| Storage | Use within 30 days of first use Store at 2–8°C / 35–46°F Protect from sunlight. Do not freeze. |
Sequence: Tyr-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr
Synonyms: TZP, Tirzepatide Acetate, AKOS040763900, TS-10296, Tirzepatide Acetate (2023788-19-2 free base)
Research & background
Independent, research-focused reading. Educational references, not medical advice or product claims.
